狄诺塞麦上市的日期

It is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

So when will denosumab be launched?

When denosumab was released:

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA for marketing.

On May 27, 2019, Amgen China announced that Angavir (English trade name:

Serious infections (including cellulitis) and dermatological reactions (e.g., dermatitis, rash, eczema) have been reported; advise patients to seek immediate medical attention if they develop signs or symptoms of infection, including cellulitis; consider discontinuing treatment if severe symptoms occur.

Adverse reactions of denosumab:

Anaphylaxis (including anaphylaxis); symptoms include hypotension, difficulty breathing, throat tightness, facial and upper respiratory tract edema, pruritus, and urticaria.

Severe and occasional bone, joint, and/or muscle pain. Discontinue use if severe symptoms occur.

Report atypical femoral fractures; risk increases with longer treatment; events occurring during and after treatment; evaluate patients with thigh or groin pain to rule out femoral fracture.